کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5527556 | 1401588 | 2016 | 8 صفحه PDF | دانلود رایگان |
- Mature blood cells can be produced ex vivo by recapitulating in vivo processes.
- Scalable blood cell generation is a critical step for obtaining transfusion products.
- Hematopietic stem cell generation has not yet been achieved, but advances are being made.
- Insight from human development will improve our ability to make blood cells in vitro.
Allogeneic hematopoietic stem cell transplantation and blood cell transfusions are performed commonly in patients with a variety of blood disorders. Unfortunately, these donor-derived cell therapies are constrained due to limited supplies, infectious risk factors, a lack of appropriately matched donors, and the risk of immunologic complications from such products. The use of autologous cell therapies has been proposed to overcome these shortcomings. One can derive such therapies directly from hematopoietic stem and progenitor cells of individuals, which can then be manipulated ex vivo to produce the desired modifications or differentiated to produce a particular target population. Alternatively, pluripotent stem cells, which have a theoretically unlimited self-renewal capacity and an ability to differentiate into any desired cell type, can be used as an autologous starting source for such manipulation and differentiation approaches. Such cell products can also be used as a delivery vehicle for therapeutics. In this review, we highlight recent advances and discuss ongoing challenges for the in vitro generation of autologous hematopoietic cells that can be used for cell therapy.
Journal: Experimental Hematology - Volume 44, Issue 10, October 2016, Pages 887-894